Upload
abhimanyu-makane
View
215
Download
2
Embed Size (px)
Citation preview
Post Exposure Prophylaxis Post Exposure Prophylaxis for HIVfor HIV
Dr Abhimanyu MakaneMBBS CHIV FHM(CMC,Vellore) AAHIVSConsultant HIV PhysicianSterling Multispecialty Hospial,Nigdi,PuneAditya Birla Memorial Hospital,Pune
Can someone become HIV Can someone become HIV negative after diagnosis???negative after diagnosis???Mississippi BabyThe Berlin Patients
Outline Outline Principal changes from previous
PEP guidelinesHealth care personnel and
exposureRisk of transmission of HIVRecommendations for the management
of person potentially exposed to HIV◦HIV PEP
Source patient testing Timing and duration of PEP Selection of PEP drugs
◦Follow-up of exposed person Post-exposure testing Monitoring and management of PEP toxicity
Basis of PresentationBasis of PresentationWHO Adult ARV guidelines
supplement-Dec 2014DHHS Aug 2013 PEP guidelines
Principal Changes from Principal Changes from Previous PEP GuidelinesPrevious PEP GuidelinesElimination of risk stratification
for exposure incidents3-drug (or more) PEP regimen for
all
Occupational Risk Exposures Occupational Risk Exposures in HCPin HCPPercutaneous
injury (needle-stick, cut)
OR
Contact of mucous membrane or non-intact skin
WITH:
•Blood•Tissue•Other potentially infectious body fluids-(CSF, synovial, pleural, pericardial, peritoneal, or amniotic fluids; semen or vaginal secretions)
NOT Considered Infectious NOT Considered Infectious for HIV for HIV FecesNasal SecretionsSalivaSputum
Sweat TearsUrine Vomitus
Risk of Transmission of Risk of Transmission of HIVHIV
Assessment of the exposed Assessment of the exposed personperson4th generation ELISA for HIV HBV
◦Vaccination status
Source Patient HIV Source Patient HIV TestingTestingIf possible, determine the HIV status of
exposure source ◦ Unknown HIV status◦ Window period
HBVHCV
Timing and Duration of Timing and Duration of PEPPEPEffect inversely proportional to time to
initiation◦ ASAP preferably within hours◦ Point at which no benefit -not definedPEP should be taken for 4 weeks, if
tolerated◦ Appeared protective in occupational and
animal studies
Post-exposure prophylaxis Post-exposure prophylaxis ARV regimens-for AdultsARV regimens-for AdultsTDF + 3TC (or FTC)
◦The preferred backboneRAL, LPV/r, ATV/r or DRV/r
◦Preferred third drugEFV
◦Alternative options
ARV contraindicated as ARV contraindicated as PEPPEPNevirapine
Special ConsiderationsSpecial ConsiderationsPregnantBreastfeedingPaediatric
Follow-up of Exposed Follow-up of Exposed PatientPatient If 4th-generation (p24 Ag/HIV Ab test) is
used: HIV testing at baseline, 6 weeks, 12 weeks
after exposureBarrier Protection for partner protection Close follow-up to diagnose toxicities early
Assess
Counsel &
Support
Prescriptio
n
Followup
• Clinical assessment of exposure• Eligibility assessment for HIV PEP• HIV testing of exposed people and source if possible
• Risk of HIV• Risks and benefits of HIV PEP• Adherence counselling if PEP to be prescribed
• PEP should be initiated ASAP post exposure• 28-day prescription
• HIV test at 3 months after exposure• Link to HIV treatment if possible• Provision of prevention intervention as appropriate